Specific β1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia

Journal of Hypertension

Volumn 25, Issue 1, 2007, Pages 197-205

  Arnold, Anne Sophie ^a   Tang, Yao Liang ^a,b   Qian, Keping ^a   Shen, Leping ^a   Valencia, Valery ^a   Phillips, Michael Ian ^a,b   Zhang, Yuan Clare ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b KECK GRADUATE INSTITUTE   (United States)

Author keywords

Blood pressure; Heart function; Myocardial infarction; RNA interference; adrenergic receptor; blockers

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LIPOSOME; SMALL INTERFERING RNA; ANTIHYPERTENSIVE AGENT; MESSENGER RNA;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ELECTROCARDIOGRAM; GENE SILENCING; GENE THERAPY; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR GENE; RNA ANALYSIS; RNA SEQUENCE; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; GENETIC TRANSFECTION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RNA INTERFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; TIME; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; BLOOD PRESSURE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HEART VENTRICLES; HYPERTENSION; MALE; MICE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; VENTRICULAR FUNCTION, LEFT;

EID: 33845365806     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000254374.73241.ab     Document Type: Article

References (35)

1. Fonarow GC. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J 2005; 149:984-993.
2. Staffileno BA. Treating hypertension with cardioprotective therapies: the role of ACE inhibitors, ARBs, and beta-blockers. J Cardiovasc Nurs 2005; 20:354-364.
3. Franciosa JA. Beta-adrenergic blocking agents: past, present, and future perspectives. Coron Artery Dis 1999; 10:369-376.
4. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Three-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. Lancet 1998; 351:1180-1181.
5. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 1997; 80:15J-19J.
6. Metra M, Cas LD, di Lenarda A, Poole-Wilson P. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 2004; 9:123-130.
7. Tang WH, Militello M, Francis GS. In heart failure, all beta-blockers are not necessarily equal. Cleve Clin J Med 2003; 70:1081-1087.
8. del Monte F, Kaumann AJ, Poole-Wilson PA, Wynne DG, Pepper J, Harding SE. Coexistence of functioning beta 1- and beta 2-adrenoceptors in single myocytes from human ventricle. Circulation 1993; 88:854-863.
9. Holmer SR, Kaissling B, Putnik K, Pfeifer M, Kramer BK, Riegger GA, et al. Beta-adrenergic stimulation of renin expression in vivo. J Hypertens 1997; 15:1471-1479.
10. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999; 96:7059-7064.
11. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 30-kinase. Circ Res 2000; 87:1172-1179.
12. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000; 101:1707-1714.
13. Sioud M. siRNA delivery in vivo. Meth Mol Biol 2005; 309:237-249.
14. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327:761-766.
15. Zhang YC, Bui JD, Shen L, Phillips MI. Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation 2000; 101:682-688.
16. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004; 117:3-10.
17. Zhang YC, Kimura B, Shen L, Phillips MI. New beta-blocker: prolonged reduction in high blood pressure with beta(1) antisense oligodeoxynucleotides. Hypertension 2000; 35:219-224.
18. Abrahamsson T, Almgren O, Carlsson L. Ischemia-induced noradrenaline release in the isolated rat heart: influence of perfusion substrate and duration of ischemia. J Mol Cell Cardiol 1983; 15:821-829.
19. Richardt G, Blessing R, Schomig A. Cardiac noradrenaline release accelerates adenosine formation in the ischemic rat heart: role of neuronal noradrenaline carrier and adrenergic receptors. J Mol Cell Cardiol 1994; 26:1321-1328.
20. Ihl-Vahl R, Marquetant R, Bremerich J, Strasser RH. Regulation of beta-adrenergic receptors in acute myocardial ischemia: subtype-selective increase of mRNA specific for beta 1-adrenergic receptors. J Mol Cell Cardiol 1995; 27:437-452.
21. Persad S, Panagia V, Dhalla NS. Role of H2O2 in changing beta-adrenoceptor and adenylyl cyclase in ischemia-reperfused hearts. Mol Cell Biochem 1998; 186:99-106.
22. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999; 100:2210-2212.
23. Patterson AJ, Zhu W, Chow A, Agrawal R, Kosek J, Xiao RP, et al. Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart. Crit Care Med 2004; 32:1041-1048.
24. Hall JA, Kaumann AJ, Brown MJ. Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium. Circ Res 1990; 66:1610-1623.
25. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiacmyocyte apoptosis. J Cell Physiol 2001;189:257-265.
26. Paroo Z, Corey DR. Challenges for RNAi in vivo. Trends Biotechnol 2004; 22:390-394.
27. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-178.
28. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9:347-351.
29. Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 2005; 12:321-328.
30. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucl Acid Drug Dev 2003; 13:1-7.
31. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296:1000-1004.
32. Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol 2003; 30:96-102.
33. Garber K. Better blocker: RNA interference dazzles research community. J Natl Cancer Inst 2003; 95:500-502.
34. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents A comparative analysis. J Biol Chem 2003; 278:7108-7118.
35. Hemmings-Mieszczak M, Dorn G, Natt FJ, Hall J, Wishart WL. Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant rat P2X3 receptor. Nucl Acids Res 2003; 31:2117-2126.